Virpax Pharmaceuticals, Inc. (VRPX) 10-Year Financial Performance & Capital Metrics

VRPX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPain Management & CNS Disorders

AboutVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Show more

Revenue $0
EBITDA -$11.99B -78828.8%
Net Income -$12.07B -79344.5%
EPS (Diluted) -2836.41 -21769.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM55.44%

ROCE

10Y Avg-106.82%

5Y Avg-106.82%

3Y Avg-125.15%

Latest-

Peer Comparison

Pain Management & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
VRPXVirpax Pharmaceuticals, Inc.	13.67K	0.01	0

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-
Operating Expenses+	2.63M	3.18M	4.2M	12.03M	21.85M	15.69M	12.08B
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	1.48M	2.56M	2.9M	7.19M	11.08M	7.82M	6.26B
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	1.14M	622.74K	1.29M	4.84M	10.76M	5.12M	5.82B
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	4K	62.26K	194.41K	2.75M	0
Operating Income+	-2.63M	-3.18M	-4.2M	-12.03M	-21.85M	-15.69M	-12.08B
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.21%	-0.32%	-1.87%	-0.82%	0.28%	-768.92%
EBITDA+	0	0	0	0	-3.5M	-15.19M	-11.99B
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-	-	-3.34%	-788.29%
D&A (Non-Cash Add-back)	2.63M	3.18M	4.2M	12.03M	18.35M	500.28K	91.04M
EBIT	-2.63M	-3.18M	-4.19M	-11.96M	-21.65M	-15.19M	-12.17B
Net Interest Income+	0	-124.52K	-147.79K	-92.73K	0	0	0
Interest Income	0	125	148	0	0	0	0
Interest Expense	14.98K	124.64K	147.93K	92.82K	0	0	-103.75M
Other Income/Expense	-14.98K	-124.64K	-143.93K	-30.56K	194.41K	500.28K	12.71M
Pretax Income+	-2.64M	-3.31M	-4.34M	-12.06M	-21.65M	-15.19M	-12.07B
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1.04%	1.03%	1.01%	0.99%	1%	1%
Net Income+	-2.64M	-3.43M	-4.49M	-12.15M	-21.46M	-15.19M	-12.07B
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.3%	-0.31%	-1.71%	-0.77%	0.29%	-793.44%
Net Income (Continuing)	-2.64M	-3.31M	-4.34M	-12.06M	-21.65M	-15.19M	-12.07B
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.53	-6.58	-9.07	-10.37	-18.32	-12.97	-2836.41
EPS Growth %	-	-11.42%	-0.38%	-0.14%	-0.77%	0.29%	-217.69%
EPS (Basic)	-0.53	-6.58	-9.07	-10.37	-18.32	-12.97	-2836.41
Diluted Shares Outstanding	4.95M	521.51K	494.51K	1.17M	1.17M	1.17M	4.25M
Basic Shares Outstanding	4.95M	521.51K	494.51K	1.17M	1.17M	1.17M	4.25M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	61.5K	46.72K	73.07K	39.57M	19.67M	9.63M	1.56B
Cash & Short-Term Investments	48.37K	41.54K	54.8K	36.84M	19M	9.14M	1.51B
Cash Only	48.37K	41.54K	54.8K	36.84M	19M	9.14M	1.51M
Short-Term Investments	0	0	0	0	0	0	1.51B
Accounts Receivable	0	1.39K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	3.33K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	10.5K	467	535	2.57M	496.27K	283.37K	42.56M
Total Non-Current Assets+	0	0	392.34K	0	0	0	0
Property, Plant & Equipment	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	392.34K	0	0	0	0
Total Assets+	61.5K	46.72K	465.41K	39.57M	19.67M	9.63M	1.56B
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-0.24%	8.96%	84.03%	-0.5%	-0.51%	160.57%
Total Current Liabilities+	1.25M	2.78M	3.66M	2.09M	3.09M	7.69M	2.47B
Accounts Payable	6.55K	3.5K	22.11K	19.84K	37.64K	18.46K	0
Days Payables Outstanding	-	-	-	-	-	-	-
Short-Term Debt	500K	1.26M	543.99K	0	0	0	0
Deferred Revenue (Current)	-6.55K	-3	-1000K	0	0	0	0
Other Current Liabilities	7.46K	819.61K	1.03M	0	2M	6M	2.47B
Current Ratio	0.05x	0.02x	0.02x	18.96x	6.36x	1.25x	0.63x
Quick Ratio	0.05x	0.02x	0.02x	18.96x	6.36x	1.25x	0.63x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	500K	0	1.02M	0	1.09K	0	0
Long-Term Debt	0	0	1.02M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	1.25M	2.78M	4.68M	2.09M	3.09M	7.69M	2.47B
Total Debt+	500K	1.26M	1.57M	0	0	0	0
Net Debt	451.63K	1.22M	1.51M	-36.84M	-19M	-9.14M	-1.51M
Debt / Equity	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-175.34x	-25.53x	-28.36x	-129.55x	-	-	-
Total Equity+	-1.19M	-2.73M	-4.22M	37.48M	16.58M	1.93M	-913.76M
Equity Growth %	-	-1.29%	-0.54%	9.89%	-0.56%	-0.88%	-473.39%
Book Value per Share	-0.24	-5.24	-8.53	32.00	14.16	1.65	-214.78
Total Shareholders' Equity	-1.19M	-2.73M	-4.22M	37.48M	16.58M	1.93M	-913.76M
Common Stock	29	30	31	117	117	12	149
Retained Earnings	-3M	-6.31M	-10.65M	-22.7M	-44.35M	-59.54M	-71.61B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.8M	-1.13M	-1.38M	-14.54M	-17.85M	-9.85M	-16.71B
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	0.37%	-0.22%	-9.5%	-0.23%	0.45%	-1695.09%
Net Income	-2.64M	-3.31M	-4.34M	-12.06M	-21.65M	-15.19M	-12.07M
Depreciation & Amortization	0	0	0	0	0	0	0
Stock-Based Compensation	384.95K	678.15K	1.47M	974.23K	745.03K	544.77K	134.7M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	14.98K	564.64K	153.22K	-61.82K	745.03K	599.43K	-16.83B
Working Capital Changes	441.37K	931.89K	1.33M	-3.4M	3.06M	4.19M	-4.78M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	454.5K	923.94K	1.34M	-686.78K	-993.1K	0	0
Cash from Investing+	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	1.67M	1.13M	1.4M	51.33M	0	0	9.08B
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	625K	-50.88K	-5.19M	0	0	9.08B
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.8M	-1.13M	-1.38M	-14.54M	-17.85M	-9.85M	-16.71B
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	0.37%	-0.22%	-9.5%	-0.23%	0.45%	-1695.09%
FCF per Share	-0.36	-2.17	-2.80	-12.41	-15.24	-8.41	-3928.38
FCF Conversion (FCF/Net Income)	0.68x	0.33x	0.31x	1.20x	0.83x	0.65x	1.38x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-73.04%	-79.37%	-164.09%	-
Interest Coverage	-175.34x	-25.53x	-28.36x	-129.55x	-	-	-
FCF Conversion	0.68x	0.33x	0.31x	1.20x	0.83x	0.65x	1.38x

Frequently Asked Questions

Growth & Financials

Virpax Pharmaceuticals, Inc. (VRPX) grew revenue by 0.0% over the past year. Growth has been modest.

Virpax Pharmaceuticals, Inc. (VRPX) reported a net loss of $12.1M for fiscal year 2024.

Dividend & Returns

Virpax Pharmaceuticals, Inc. (VRPX) had negative free cash flow of $16.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener